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by
ZACHARY CLAYBORNE DIETRICH
(Under the Direction of Shauna Joye)
ABSTRACT
A plethora of research has investigated PTSD treatment outcomes among Veterans of
foreign wars. However, research has suggested mixed treatment efficacy. Although investigations
into factors that may help predict treatment outcomes are emerging, to date no study has
evaluated treatment choice among Veteran populations. Previous treatment choice studies have
yielded qualitative and quantitative information that can be useful in clinical decision-making.
This study looks to build upon the treatment choice literature with combat Veterans to evaluate
for underlining characteristics of cohorts that will help build upon existing knowledge. It has
been suggested that treatment benefits Vietnam Era Veterans more than younger generations of
Veterans. One of the suggested predictive factors of outcome is treatment choice; implying
preference would differ between cohorts. This study did not lend evidence of different treatment
preference between cohorts. Predictive factors were obtained for each treatment that could
provide future research with data for hypothesis testing to improve the treatment selection
process.
Index Words: Combat Veterans, Treatment Choice, PTSD

TREATMENT CHOICE AMONG COMBAT VETERANS
by
ZACHARY CLAYBORNE DIETRICH
B.S., Indiana University, 2007
M.A., Cleveland State University, 2012

A Dissertation Submitted to the Graduate Faculty of Georgia Southern University in
Partial Fulfillment of the Requirements for the Degree
DOCTOR OF PSYCHOLOGY
STATESBORO, GEORGIA

© 2017
ZACHARY CLAYBORNE DIETRICH
All Rights Reserved

1
TREATMENT CHOICE AMONG COMBAT VETERANS
by

ZACHARY CLAYBORNE DIETRICH

Major Professor: Shauna Joye
Committee:
Janie Wilson
Lawrence Locker

Electronic Version Approved:
May, 2017

2
DEDICATION
To Evelyn May & William Zachary Dietrich I
Von den Hallen der meiner Vorfahren, ihr Einfluss ist bei mir.

3
ACKNOWLEDGEMENTS
I first want to thank those who were not part of this project, but whose influence deserves
mention.
Richard Rakos: Through our conversations that usually became excruciating thought
exercises, I learned to see through the lens of science, question through the art of logic, and more
importantly know when each of these skills should be practiced. A lesson few in our field, to
their detriment, receive or faithfully adhere too. Your guidance and support permanently crushed
what little doubt I had in my own intellectual ability, perhaps to the annoyance of many after
you.
Michael Wisniewski: Your larger than life presence provided a model I will always strive
to emulate. Switching between egotistical and modest, omniscient and ignorant, conceding and
disputing; you always seemed to know exactly what others need from you whether they
recognize it at the time or not. You will always be my mentor and friend, no matter how many
times you order ridiculously over-priced scotch when it is my turn to pick up the bill.
Don and Cindy Sykes: Last, but certainly not least, I struggle to convey in a few
sentences the impact you have made. I understand how fortunate I have been to work with you
and get the missing piece that is an unfortunate weakness in all graduate training programs; true
professional development. The best part of ending my academic education is knowing I am about
to enter a much more challenging, but more rewarding, phase in my education and I could not
ask for better teachers, mentors, and friends.
To the committee on this project, your contributions to this project are miniscule
compared to the countless lessons I’ve learned from each of you over the years. I find it no

4
coincidence my specialization and interest within our field draws from the courses your three
taught; sometimes, but not often, even practicum.
Janie Wilson: The first at Georgia Southern I considered a mentor. Even from our first
conversation standing in the lobby, and standing three feet shorter than me, I knew I was talking
to a beast. I unfortunately only took one course you taught, but it was the most important course I
ever took for my career. Among all the neuropsychology books in my office are the books and
notes from your lectures; and they are frequently referenced. The time I spent in your lab was
just as valuable; there are too many lessons from that time of my educations to put here. Thank
you.
Lawrence Locker: I did not need to take your statistics course since previous credits
carried over. I never regretted the decision to enroll in that course anyway. That, and your other
course, proved invaluable with what I do today. More importantly, I appreciated your open and
honest display for passions outside of our field. It was a breath of fresh air to talk with someone
who had mastered their profession, but had interest and ambitions outside of our narrow world. It
brought a “realism” to working with you that was not the same old tune, fiddle, and guitar. For so
many others, it’s been the same way for years.
Shauna Joye: I really have no idea where to begin or what to say. I still cannot believe we
were so tired at the airport in Portland Maine that we thought we saw unicorns, then drove 16
hours, slept two, and then climbed the highest mountain that state had to offer. I cannot wait to
see where our work takes us next.

5

TABLE OF CONTENTS
DEDICATION ................................................................................................................................2
ACKNOWLEDGMENTS ..............................................................................................................3
CHAPTER
1 INTRODUCTION ...........................................................................................................8
Statement of the Problem.........................................................................................8
Background and Significance .................................................................................8
Purpose……………………... ...............................................................................10
Definition of Terms ...............................................................................................10
2 LITERATURE REVIEW ..............................................................................................15
PTSD………………………………… .................................................................15
Physiological impact..................................................................................17
Cognitive impact........................................................................................18
Social Impact……………….....................................................................20
Treatment Effectiveness Among Veterans ...........................................................20
VA Treatments...........................................................................................24
Cognitive Processing Therapy...................................................................24
Prolonged Exposure…...............................................................................25
Eye movement desensitization and reprocessing.......................................27
Selective serotonin reuptake inhibitors......................................................27
Barriers To Treatment............................................................................................28
Individual Barriers.....................................................................................28

6
Institutional Barriers.................................................................................29
Societal Barriers…………………………................................................31
PTSD Treatments Revisited: Beyond the VA........................................................33
Wilderness Experience Programs…………..............................................33
D-Cycloserine with exposure therapy........................................................34
SSRI with psychotherapy...........................................................................35
Previous PTSD Treatment-Choice Studies............................................................36
Current Study.........................................................................................................37
3 METHODOLOGY ........................................................................................................39
Participants ............................................................................................................39
Materials and Procedure .......................................................................................39
4 RESULTS ......................................................................................................................42
5 DISCUSSION ................................................................................................................46
Treatment Endorsement…………………………………………….....................46
Treatment Endorsement Predictors…………...…………………….....................47
Exposure................................................................................................................46
Possible Clinical Application of the Current Study...............................................47
Limitations.............................................................................................................51
Future Directions...................................................................................................51
REFERENCES..............................................................................................................................53
APPENDIX A................................................................................................................................83
APPENDIX B................................................................................................................................88
APPENDIX C................................................................................................................................89

7
APPENDIX D................................................................................................................................90
APPENDIX E................................................................................................................................91
APPENDIX F................................................................................................................................92

8
CHAPTER 1: INTRODUCTION
Statement of Problem
Department of Defense (DoD) released that after seven years of the War of Terror, 25%
of combat Veterans from post-9/11 conflicts will meet criteria for posttraumatic stress disorder
(PTSD; Department of Defense, 2010). In fact, five years after the invasion of Iraq, mental
disorders were the second most frequent category of diagnosis at Veterans Affairs (VA) hospitals
(Tanielian & Jaycox, 2008). The Veterans Health Administration (VHA) has received additional
funds to treat this influx of combat Veterans seeking services. The VHA expanded programs that
originated to treat Vietnam Veterans, with the inherent assumption that these programs would
benefit all combat Veterans (Erbes, Curry, & Leskela, 2009). The VHA’s efforts to treat post-9/11
Veterans have been called into question since differing rates of treatment effectiveness and
attendance have been observed in Vietnam era and post-9/11 combat Veterans (Chard Schumm,
Owens, & Cottingham, 2010).
Background and Significance
PTSD is one of the primary difficulties faced by returning combat Veterans (Hoge et al.,
2004). PTSD is frequently described as a collection of hyper-responsive and inappropriate “fight
or flight” responses (Yehluda, 2001). The term “fight or flight” first appeared in 1915 when
Walter Cannon theorized that the physiological purpose of this response was an adaptive
response to threat (Shiromani, Keane, & LeDoux, 2009). However, with PTSD the fight or flight
mechanism that is adaptive during the trauma persists post-trauma and is associated with
significant behavioral, cognitive, and social impairment (Hoge, 2010).
Despite statistics illustrating that post-9/11 combat Veterans return from combat with
significant psychological difficulties, post-9/11 combat Veterans are significantly less likely than
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in Vietnam era Veterans to take advantage of available treatment options (Chard et al., 2010;
Erbes, Curry, & Leskela, 2009). Although such factors as employment, family commitments, and
symptom presentation are not supported as being associated with treatment use (Mott, Hundt,
Sansgiry, Mignogna, & Cully, 2014; Erbes, Westermeyer, Engdahl, & Johnson, 2007), “Veteranera cohort” is highlighted as a predictive factor in who will attend treatment, with Vietnam era
Veterans more likely to attend and benefit from mental health treatment than post-9/11 Veterans
(Hundt et al., 2014; Erbes et al., 2009).
Veteran opinion about the usefulness of different types of treatment is one area of inquiry
that could lend an understanding to treatment utilization. Simply put, we need to know what
kinds of treatments Veterans are willing to try. The literature is absent of treatment choice studies
relevant to military populations. However, previous treatment choice studies relevant to the
PTSD literature exist and focus on female sexual assault survivors (Cochran, Pruitt, Fukuda,
Zoellner, & Feeny 2008; Zoellner, Feeny, Cochran, & Pruitt 2003; Zoellner, Feeny, & Bittinger,
2009). These studies have yielded meaningful information that could provide evidence for
treatment use in clinical settings. For example, an evaluation of a behavioral treatment designed
to use extinction and habituation, prolonged exposure (PE) therapy, compared to the medication
sertraline, a selective serotonin reuptake inhibitor produced primarily to treat depression,
indicated that PE was preferred and perceived to be more effective in a sample of women who
had no history of trauma (Cochran et al., 2008). However, when replicated among a sample of
trauma-exposed women, the results suggested that a combination of PE and sertraline was
preferred (Pruitt et al., 2012). In a qualitative evaluation comparing preference for either PE or
sertraline, trauma-exposed participants cited practicality as their reasoning for endorsing
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sertraline over PE alone (Zoellner et al., 2009). Thus, important differences may exist in
treatment choice between non-clinical and clinical populations.
Some previous studies have investigated what kinds of services combat Veterans might
want to access after deployment, but not specific treatments for mental-health issues. For
example, Sayer et al. (2010) found that combat Veterans reported Veterans were significantly less
interested in treatment than in continuing education, obtaining employment, and receiving
vocational training. However, Veterans’ lack of interest in treatment options does not reflect their
clinical presentation, as many Veterans return from combat struggling with mental-health issues
(Chard et al., 2010). Insight into factors that influence treatment choice could lead to increased
treatment-seeking among combat Veterans, a population that presents with a great need for
services (Cochran et al., 2008).
Purpose
The primary purpose of this study is to evaluate potential underlying variables that
impact treatment choice among Veterans in efforts to contribute meaningful information to
formulate treatment planning. The current study will evaluate two cohorts of differing military
generations: Vietnam era combat Veterans and post-9/11 combat Veterans. By obtaining data
about treatment choice perceptions, perceptions of stigma, symptom endorsement, and
personality, this exploratory study looks to find measures that could be used as predictive factors
to treatment preference.
Definition of Terms
Cognitive Behavioral Therapy (CBT). CBT is an evidence-based practice relying on
cognitive and behavioral principles. CBT focuses on the impact of maladaptive thinking and
behaviors on mood. CBT is considered problem focused, with the primary objective of replacing
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maladaptive patterns of thinking and behaving with adaptive ones. Although CBT originated as a
unique manualized treatment, other therapies have been developed using CBT theory and
modifications to treatment techniques. CBT is now considered an umbrella term for a large
variety of treatments.
Cognitive Processing Therapy (CPT). CPT is an adaptation of CBT theory designed to
treat PTSD. CPT posits that PTSD occurs when the beliefs about trauma produce strong negative
emotions that prevent accurate appraisals of the trauma. CPT focuses on cognitive restructuring
of the event and exercises where the client writes narratives about the trauma then later (in
session) evaluates the narratives for inaccurate appraisals.
D-Cycloserine (DCS). Originally patented under the brand name Seromycin, DCS is an
antibiotic medication developed for the treatment of tuberculosis. DCS is a partial agonist of
NMDA glutamatergic receptors in the basolateral nucleus of the amygdala. Because of this
action, studies have suggested that administration of this drug 30 to 60 min prior to a therapy
session may enhance fear extinction when individuals are exposed to fear-eliciting stimuli.
Department of Defense (DoD). The DoD is a department of the Federal United States
government under the direction of the Executive Branch. The DoD’s function is to coordinate the
involvement of any governmental operations that relate to national security or to the military.
Eye Movement Desensitization and Reprocessing (EMDR). EMDR is a treatment that
conceptualizes PTSD as symptoms that originate from disturbing memories. The belief is that
these memories are stored in an isolated memory network that inhibits adequate processing.
EMDR is similar in approach to CPT, however EMDR adds the bilateral sensory input, such as
left to right eye movement following a clinician’s finger, while talking about the memory. The
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theory is that this movement aids in adequate processing of the memory. The treatment typically
takes 12-15 weekly sessions.
Evidence Based Treatment (EBT). EBTs refer to treatments that integrate the best
available research, clinical expertise, and client characteristics. Treatments obtain EBT status
after receiving consistent replication of clinical trials in efficacy.
Operation Enduring Freedom (OEF). OEF is the official name for the Global War on
Terrorism by the United States. OEF is the ongoing conflict that began in Afghanistan on
October 7, 2001. OEF refers to operations in Afghanistan, Philippines, Somalia, Georgia,
Kyrgyzstan, Sahara, and the Caribbean of Central America.
Operation Iraqi Freedom (OIF). OIF refers to the 2003 invasion of Iraq by the United
States between March 19, 2003, and May 1, 2003. Some sources refer to OIF Veterans as any
Veteran who served in combat operations after March 19, 2003. However, the operation name
was changed after May 1 of that year. Instead of naming specific operations, much of the
literature refers to combat Veterans of engagements in Iraq or Afghanistan after October 2001
jointly as OIF/OEF Veterans.
Post-9/11 Era Veteran. Refers to a Veteran who engaged in combat after the September
11, 2001, attack on the World Trade Center in New York. These Veterans served in conflict after
October 7, 2001 in Afghanistan, Iraq, Yemen, Pakistan, and currently campaigns in Syria and
Iraq against the Islamic State of Iraq and Syria. This term is used interchangeably in other
sources as Veterans of the Global War on Terrorism.
Posttraumatic Stress Disorder (PTSD). PTSD is classified as a trauma and stressrelated disorder. PTSD occurs after an individual experiences at least one traumatic event that is
followed by psychological and physical after the trauma such as avoidance of trauma reminders,
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hyperarousal, and flashbacks of the traumatic event. These symptoms persist for over a month
after trauma.
Prolonged Exposure Therapy (PE). PE is an adaptation of CBT designed to treat
PTSD. The PE conceptualization of PTSD is that symptoms are maintained through avoiding
stimuli associated with the trauma, and this negative reinforcement strengthens the fear
associations. Therefore, core components of PE are repeated exposures to stimuli that have been
avoided since the onset of PTSD. During a typical PE exposure session, individuals are exposed
to stimuli that elicit anxiety until the sympathetic nervous system is exhausted and physical
symptoms of anxiety are no longer experienced. This occurs repeatedly until fear extinction is
achieved.
Selective Serotonin Reuptake Inhibitor (SSRI). SSRIs are a class of medication
considered to be antidepressants and prescribed for the treatment of a variety of depressive and
anxiety disorders. SSRIs limit the reabsorption of serotonin into the presynatpic cell, resulting in
an increase of serotonin in the synaptic cleft available to bind to the postsynaptic receptors.
SSRIs were developed on the theory that because decreased mood is a result of low serotonin
levels, increasing serotonin levels has positive mood altering effects.
Veterans Affairs (VA). The VA is a government institution in the United States that
serves, organizes, and disseminates benefits to American Veterans. The VA is split into three
subdivisions: Veterans Health Administration, Veterans Benefits Administration, and the
National Cemetery Administration.
Veteran’s Health Administration (VHA). The VHA is the component of the VA that is
charged with implementing health care to qualifying Veterans. The VHA is the largest integrated
health care system in the world (VA, 2017).
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Vietnam Era Veteran. Vietnam era is the term used in the United States to signify
service during the time around the Vietnam War. To classify as a Vietnam era Veteran, military
service must have occurred between February 28, 1961, and May 7, 1975. Conflicts during this
time occurred in South Vietnam, North Vietnam, Cambodia, and Laos.
Wilderness Experience Program (WEP). WEPs are organizations that conduct outdoor
programs in wilderness environments for the purpose of therapy, rehabilitation, and education.
For purposes of psychological treatment, WEPs do not have a formal structured therapeutic
component. Instead, WEPs rely on building resilience and self-efficacy through natural
consequences of the inherent challenges of living or traversing through wilderness environments.
Wilderness Therapy (WT). WT is a WEP with a formal structured therapeutic
component. No specific criteria are used to define WTs in the literature, and the term is used for
a variety of settings and treatment orientations. The therapeutic component can be based on any
theoretical orientation and ranges from “check-ins” to formal sessions such as tele-health
communication including emails, phone calls, or video-chatting.
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CHAPTER 2: LITERATURE REVIEW
Five years after the invasion of Iraq by the United States military and 7 years after the
War on Terror launched in Afghanistan, mental disorders were the second most frequent category
of diagnosis at the Veterans Affairs (VA) hospitals (Tanielian & Jaycox, 2008). In 2009, the
Department of Defense (DoD) estimated that 25% of combat Veterans – 125,000 individuals –
were believed to possibly meet criteria for posttraumatic stress disorder (PTSD; DoD, 2010).
Another report by VA officials showed that severe psychological distress among returning
combat Veterans resulted in approximately 22 combat Veterans taking their own lives every day
in 2012 (Kemp & Bossarte, 2013). However, a review of this report shows significant
methodological errors and suggests this figure is likely a significant underestimate, with only 21
states included and concerns over misclassification of the deceased as non-Veteran by
documenting authorities.
Currently, the first line of treatment for many combat Veterans is through the VA’s PTSD
clinical teams and residential programs. The VA developed these programs primarily to treat
PTSD among Vietnam-era Veterans and currently assumes its effectiveness in treating post-9/11
combat Veterans (Erbes, Curry, & Leskela, 2009). The use of VA treatment protocols has been
questioned because although comparison studies between pre- and post-9/11-era Veterans are
limited, available data suggest different treatment effectiveness and attendance across cohorts
(Chard et al., 2010). Post-9/11 combat Veterans are not benefitting as much as previous
generations of Veterans.
PTSD
The primary mental health diagnosis among combat Veterans is PTSD (Hundt et al.,
2014). PTSD is characterized by the re-experiencing of a traumatic event accompanied by
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symptoms of increased arousal, avoidance of trauma-related stimuli, and negative alterations in
cognition and mood either beginning or worsening after the traumatic event [American
Psychiatric Association (APA), 2013]. The APA first defined PTSD as an anxiety disorder in
1980. The decision to include PTSD in the third edition of the Diagnostic and Statistical Manual
(DSM-III; APA, 1980) was heavily influenced by the numerous Vietnam War Veterans who
presented with psychological distress and disability both immediately following and for many
years after their return from deployment (Neyland et al., 1998).
PTSD is considered an adaptive response to fear learning (Hoge, 2010), and the most
widely accepted model of fear learning is Pavlovian fear conditioning (Rosen & Schulkin, 1998).
Conditioning of new fears involves pairing a neutral stimulus multiple times with a stimulus that
naturally elicits a fear response. Because the stimulus that naturally elicits a fear response does
not have to be taught, it is called the unconditioned stimulus (US). The fear response to a US is
called an unconditioned response (UR). Once the neutral stimulus is paired repeatedly with the
US, it will begin to elicit a fear response, even when the US is no longer present. The neutral
stimulus is now a conditioned stimulus (CS), and the learned fear response is a conditioned
response (CR). Laboratory examples have long shown that after continued pairings, the fear
response is a learned response to the CS (Wolpe, 1982).
Interestingly, individuals with PTSD can engage in behavioral avoidance and other
symptoms of fear learning after a single pairing of the US and CS. The Rescorla-Wagner Model
(Rescorla & Wagner, 1972) illustrates how organism appraisal and expectancy can impact the
speed of learning. If the event is unexpected and the individual loses the perception of control
over his/her life or self, the fear response is conditioned faster, often immediately, and can
become chronic (Cantor, 2009). In fact, feeling as though the individual has lost control in
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fearful situations has been shown to lead to PTSD symptoms even in the absence of a specific
life-threatening event (Basolu, Livanou, & Crnobaric, 2007). Therefore, if an event was
unexpected, and the individual felt powerless or appraised the event as life threatening, the
association could be made after a single pairing of the CS and US. Support for this idea not only
comes from clinical observation, but also from animal observations in laboratory settings (Foa,
Zinbarg, and Rothbaum, 1992).
Impact of PTSD
Physiological impact. PTSD has been described as an adaptive response to a severe
stressor that has promoted survival (Hoge, 2010), and evolutionary explanations of PTSD
support this hypothesis (Cantor, 2009). That is, learning rather quickly to avoid a life-threatening
situation potentially promotes survival of the species. Initial beliefs of the physiological
mechanisms of PTSD led clinicians to believe symptoms were merely over-exaggerated
symptoms of anxiety (Yehuda, 2001). Because of this misunderstanding, treatment attempts were
misguided, and some led to worsening of symptoms. One frequent iatrogenic effect occurred
with heavy reliance on benzodiazepines (Raskind, 2009), a GABAA agonist used to treat anxiety
that induces sedation and has a high addiction potential (Stahl, Grady, & Munter, 2005). New
discoveries have recognized that PTSD is not just an over-exaggerated stress response but a
condition with physiological markers that differ from an anxiety diagnosis. Differences in the
clinical profile may be too poorly understood to consistently treat with prescription medications.
For example the hormone cortisol is released as part of the stress response (Dickerson &
Kemeny, 2004), but studies evaluating cortisol levels among PTSD patients show differences in
response. Although cortisol levels in some patients were significantly elevated, levels in others
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were significantly decreased. Meaning that although symptom presentation was consistent,
physiological differences existed (Yehuda, 2001).
Cognitive impact. One of the common features of PTSD is the pervasive change in
memory related to the trauma, with some aspects of memory enhanced and others diminished.
For example, memories of the trauma might occur repeatedly and often manifest as reexperiencing symptoms, such as unwanted, distressing, and poorly controlled recollections of the
traumatic event (Verfaellie & Vasterling, 2009). Alternatively, another diagnostic symptom of
PTSD is the inability to recall important aspects of the traumatic event (APA, 2013).
In addition to memory related to the trauma, general autobiographical memory and ability
to encode and retrieve new information may also be observed in those with PTSD. Using the
Autobiographical Memory Test (AMT), researchers found that although Vietnam-era Veterans
with PTSD could recall general information about autobiographical memories encoded after the
trauma but had trouble with recalling specific information. In contrast, trauma survivors without
a PTSD diagnosis were better able to recall specific information about autobiographical
information (McNally, Lasko, Macklin & Pitman, 1995). The AMT requires verbal cues, but
similar results in a civilian population with PTSD were observed when visual cues were used
(Schonfeld & Ehlers, 2006). This provides evidence that memory deficits are present across
different types of perceptual cues. Moreover, when evaluating memory content, positive
memories are recalled with significantly less detail than negative memories in those with a PTSD
diagnosis (McNally et al., 1995).
Difficulties in memory can have significant treatment implications. An individual’s sense
of self is strongly tied to defining autobiographical memories (Beck, 2011). When asked to recall
self-defining memories, individuals with PTSD reported more trauma-related memories and
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memories of negative emotional valence than positive or neutral memories (Sutherland &
Bryant, 2005). This prevalence in recall of negative memories can skew perceptions of self in
many facets of functioning that additionally complicate treatment and require clinical attention
(Beck, 2011).
Although some suggest that memory impairment is a predictive factor for who will
develop PTSD after trauma, evidence suggests that the relationship may actually be the opposite.
That is, memory impairment likely occurs as a result of trauma. In Veterans assessed before and
after one deployment to Iraq, declines in verbal and visuospatial memory were observed only in
those with psychological symptoms of trauma after deployment (Vasterling et al., 2006).
Observations such as this have led some to speculate that symptoms of PTSD occur only if the
traumatic event first leads to the physiological response that then may impair memory (Rubin,
Berntsen, & Bohni, 2008).
Findings regarding the physiological causes of memory impairments among those with
PTSD have been fairly consistent (Verfaellie & Vasterling, 2009). One explanation is that the
hippocampus may experience neuronal degeneration due to the neurotoxicity of significantly
elevated glucocorticoid responsiveness (Yehuda, 2001). In support of this explanation, Vietnam
Veterans with PTSD showed a significant 8% reduction in hippocampal volume compared to
Vietnam Veterans without a PTSD diagnosis (Bremmer et al., 1995). This reduction in volume
was associated with a 40% deficit on scores of verbal memory tasks as measured by the Wechsler
Memory Scale.
If left untreated, memory difficulties associated with PTSD are seen across the lifespan,
with a steeper decline in memory formation and recall observed in elderly patients with PTSD
and compared to their cohort without a PTSD diagnosis (Yehuda et al., 2006), thus potentially
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making activities of daily living more difficult as individuals with PTSD age. Memory
impairments caused by PTSD have consequences beyond the cognitive domain. Impaired
memory has been shown to lead to physical health consequences, with data suggesting that those
with a diagnosis of PTSD and heart disease were 80% more likely to forget taking necessary
medications for heart disease than the control group with heart disease but not PTSD (Zen et al.,
2012). However, memory impairment after trauma is not necessarily permanent. Evidence
suggests that after completing cognitive behavioral therapy (CBT) for PTSD, a decrease in PTSD
symptoms was associated with improved memory retrieval, particularly in response to positive
cues (Sutherland & Bryant, 2007).
Social impact. Interpersonal problems are among the most significant concerns of
returning combat Veterans (Milliken, Auchterlonie, & Hoge, 2007; Dekel & Monson, 2010).
Symptoms of PTSD such as hyper-vigilance, increased sensitivity to perceived threats, and
behavioral avoidance frequently erode interpersonal resources needed to maintain social support
(Brancu et al., 2014). For example, one study showed that over half (57%) of combat Veterans
reported difficulties controlling their anger (Sayer et al., 2010). In addition, lack of social support
has long been established as the greatest predictive factor in developing and maintaining PTSD
after a traumatic event (Brewin, Andres, & Valentine, 2000).
Treatment Effectiveness Among Veterans
Shortly after the wars in Iraq and Afghanistan began, PTSD was reported to be the most
present concern faced by returning combat Veterans (Hoge et al., 2004). This concern was
previously shown among Vietnam Veterans as well (Zatzick et al., 1997). Treatments that show
general efficacy within civilian populations only show limited efficacy within Veteran
populations (Schnurr et al., 2003) Since this discrepancy was first reported, several possible
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explanations have been postulated. One explanation involves combat Veterans waiting to seek
treatment until symptoms become severe (Bradley et al., 2005). Greater symptom expression
leads to increased treatment difficulty and typically requires more intensive treatment. Another
possible influence on treatment outcomes is the tendency for combat Veterans to limit social
interactions, including treatment, in fear of displaying symptoms to others. When limiting social
interactions, it is hypothesized that the avoidance behaviors diminish opportunities to habituate
to fear-provoking stimuli and significantly decrease social support, a high frequency of both are
necessary for the natural stress recovery to occur. Finally, it is suggested that compensation
through disability claims provide reinforcement to continually display symptoms. In this view,
Veterans are not as motivated to recover from symptoms as civilians because of secondary gains.
Some support does exist for this claim. Cully and colleagues (2008) found that Veterans with at
least a 50% service connection who receive increased access and benefits are less likely to attend
treatment.
Treatment of post-9/11 Veterans does not appear to be as attractive or efficacious as with
Vietnam Veterans. Data collected at a number of VA hospitals and supported by clinician
consensus based on clinical observation suggest that post-9/11 Veterans who actively seek
treatment are less likely to attend treatment regularly and more likely to completely abandon
treatment (Erbes et al., 2009). Symptom presentation was suggested as a casual factor, as
depression and treatment attendance are negatively correlated among post-9/11 Veterans (Erbes,
et al., 2007). However, comparisons between post-9/11 Veterans to Vietnam Veterans showed
that cohort was a stronger predictive factor than symptoms (Erbes et al., 2009), with Vietnam
Veterans more likely to seek out and attend treatment. Another study showed that patient age was
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the only significant predictive factor (Hundt et al., 2014). Further evaluation of the mediators
associated with age is needed to understand this relationship.
Treatment is more likely to be prematurely terminated by post-9/11 Veterans and then
reinitiated under a crisis situation requiring more intensive treatment (Mott, Hundt, Sansgiry,
Mignogna, & Cully, 2014). Even with a formal diagnosis of PTSD, one study showed that only
35% of post-9/11 Veterans sought treatment within one year (Culley et al., 2008). Caregivers’
reports also lend evidence that symptom severity is not a satisfactory explanation for differential
treatment seeking behaviors between the cohorts. Of respondents, 64% of caregivers who cared
for a post-9/11 combat Veteran reported a mental health diagnosis as opposed to 36% of pre-9/11
combat Veterans. Moreover, 75% of post-9/11 caregivers reported they had to provide assistance
to their Veteran in coping with stressful situations, as opposed to only 46% among pre-9/11
Veteran caregivers (Ramchand et al., 2014).
Evaluating the multitude of factors that could be influencing treatment seeking behaviors
and subsequent adherence has yielded several possibilities, although it is unlikely that a single
cause has led to this discrepancy. One factor to consider is that the number post-9/11 Veterans
wounded in combat is significantly higher than previous American wars (Carlock, 2007).
Furthermore, Vietnam Veterans typically served one year-long tour. In contrast, post-9/11
Veterans typically serve multiple deployments and many have been injured, recovered, and
redeployed (Hafemeister & Stockey, 2010). This pattern of deployment could be a significant
factor because frequency and intensity of combat experiences are among the strongest predictors
of future PTSD symptoms (Department of Veterans Affairs, 2010).
Survival rates of Veterans wounded in action are another suggested factor for increased
PTSD provenance rates in recent combats. Early into the wars in Iraq and Afghanistan, the
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survival rate of wounded individuals reached approximately 90% due to technological advances
in body armor, improved understanding and training of field combat medicine, and increased
efficiency in evacuating the wounded (Gawande, 2004). The wounded-to-killed ratio of the
Vietnam War was 2.6 to 1, whereas the wounded-to-killed ratio of Afghan and Iraqi wars was 15
to 1 (Hafemeister & Stockey, 2010). Although this increase in combat survival is clearly a
positive change, injuries significantly alter quality of life for combat Veterans after
injury/trauma. As of 2006, more than half of combat-wounded Americans suffered brain damage
that resulted in permanent changes in their cognition, mood, and behavior, thus severely
impacting their ability to successfully reintegrate to civilian life (Friedman, 2006).
Epidemiological studies suggest that Vietnam-era and post-9/11 Veterans present to
treatment with different concerns that could influence treatment efficacy. For example, Vietnam
Veterans are more likely to report substance use disorders. On the other hand, post-9/11 Veterans
are more likely to report difficulties with anger management and violent behavior than Vietnam
Veterans. Despite injuries suffered during combat, post-9/11 Veterans are less likely to file a VA
disability claim citing a PTSD diagnosis (Fontana & Rosenheck, 2008). Other characteristics are
suggested based on clinical observation, such as reliance on technology, gender, and marital
status. However, additional quantification is necessary to validate these claims and understand
their impact on diagnosis and treatment. Despite low treatment attendance, data supports that
post-9/11 combat Veterans are concerned with reintegration and interested in resources to assist
in the transition. VA researchers found that 96% of respondents were interested in services that
focused on reintegration (Sayer et al., 2010).
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VA Treatments
In 2010, the Department of Veteran Affairs released Management of Post-Traumatic
Stress to serve as a clinical guideline for treating PTSD (DVA, 2010). Approximately 50
clinicians from the VA and DoD developed the guidelines with the goal of evaluating evidence
for treatments that emerged since the previous guidelines in 2004. The group unanimously
supported the use of treatments developed from a CBT framework. However, as of 2009, none of
these treatments were designed around theory or literature specifically on Veteran populations
(Erbes et al., 2009).
Cognitive processing therapy. Cognitive Processing Therapy (CPT) focuses on
challenging and modifying maladaptive beliefs that are considered stuck points in recovery
(Resnick, Monson, & Chard, 2007). The addition of writing trauma narratives serves as an
exposure component of the treatment (Resnick, Monson, & Chard, 2007). The manual allows for
flexibility regarding setting as CPT can be practiced in an individual or group setting.
Research evaluating the efficacy of CPT in Veteran populations has demonstrated
symptom reduction when compared to waitlist controls (Monson et al., 2006). Unfortunately, no
studies have dismantled the components of CPT to assess efficacy for this population. Only one
treatment dismantling study has been conducted at the time of this manuscript and it was
conducted using a population of female sexual assault survivors (Resick et al., 2008).
Participants were assigned to one of three groups receiving either CPT, the cognitive therapy
component alone, or the written exposure alone. The full CPT condition and the cognitive-only
condition showed no significant difference, but the narrative component was significantly less
effective in reducing PTSD symptoms immediately after treatment. However, the withinparticipant design of this study yielded a decrease in PTSD symptoms across all three groups. All

25
groups still showed mild PTSD symptom reduction at the 6-month follow-up, but there were
statistically nodifferences among groups . This finding lent evidence that the combination of
treatment components was as effective as the individual parts in isolation at follow-up.
In the initial study using CPT with a Veteran population, 50 Veterans, all with a diagnosis
of PTSD, completed the full 12-session treatment prescribed in the treatment manual. After
treatment, 40% no longer met criteria for PTSD, and 50% had a significant change in their
symptoms. Although re-experiencing and emotional-numbing symptoms did significantly
improve, behavioral avoidance and hyperarousal symptoms did not significantly differ from preto post-treatment (Monson et al., 2006). Additionally, in a study evaluating effectiveness in
OIF/OEF and Vietnam Veterans, CPT was shown to be effective for both cohorts. However, the
OIF/OEF cohort had a significantly lower session attendance rate than the Vietnam cohort
(Chard et al., 2010). In other words, OIF/OEF Veterans were less likely to attend treatment
sessions than their counterparts.
Since the VA began to make efforts to disseminate empirically based treatments (EBTs)
throughout the VAHs, studies have been conducted on the effectiveness of this work. Alvarez and
colleagues (2011) used a retrospective-cohort design to compare CPT with a previously assessed
treated cohort considered treatment as usual. Their results indicated significant symptom
improvement in the CPT cohort over the treatment-as-usual cohort in symptoms of PTSD,
depression, and improved quality of life (Weathers et al., 2013).
Prolonged exposure. Among treatments for PTSD, exposure-based treatments have been
studied more than other treatments (VA, 2010). Exposure treatments are designed to modify
associations between a feared stimulus (the CS) and avoidance behaviors that negatively
reinforce the fear. Exposure therapies involve repeated exposure to feared stimuli while
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practicing response prevention. By disassociating the CS and CR, the sympathetic nervous
system responses lessen over time, which leads to behavioral extinction (Abramowtiz, Deacon,
& Whiteside, 2012). Among differing exposure-based treatment options, Prolonged Exposure
(PE) is recommended for treatment by the VA. PE combines imaginal exposure and in-vivo
exposure of the traumatic event and associated stimuli (VA, 2010). In addition to the exposure
component, cognitive restructuring is a suggested, but not a required component, to strengthen
the new associations learned during the exposure (Eftekhari, Stines, & Zoellner, 2006). Imaginal
exposure to the event occurs through thinking about and vocalizing the experience in detail
(including physical and emotional descriptions). In-vivo exposure occurs through confronting the
feared stimuli in a hierarchical fashion beginning with the stimulus that is perceived to be the
easiest to confront.
Dismantling exposure-based therapies has led to mixed results in the literature on
component efficacy, particularly in the use of cognitive restructuring. For instance, a study of
civilian trauma showed a less robust decrease in symptoms of PTSD and depression if the
cognitive component was omitted (Bryant et al., 2008). However, a meta-analysis concluded that
when the focus of treatment was on decreasing behavioral avoidance only, the additional
cognitive component did not contribute to efficacy. The cognitive component is theorized to be
ineffective because the experience of challenging and restructuring thoughts is done without
clinician directives (Wolitzky-Taylor, Horowitz, Powers, & Telch, 2008). When compared to
present-centered therapy, female Veterans showed a greater decrease of symptoms with PE
(Schnurr et al., 2007), although a limitation to the study is small sample size (n = 10). Taken
together, research studies with PE provide evidence of PE effectiveness across generations and
gender (Rauch et al. 2009). Nevertheless, more Veteran-specific studies are needed on PE and
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other exposure-based treatments to obtain a deeper understanding of the therapeutic mechanisms
(VA, 2010).
Eye movement desensitization and reprocessing. Eye Movement Desensitization and
Reprocessing (EMDR) includes imaginal exposure and cognitive therapy while simultaneously
performing eye movements during the exposure (Shapiro, 1989). Although the effective
mechanism of EMDR is reported to be the bilateral movement of the eyes (Shapiro, 1989), two
meta-analyses found no support for the eye-movement component of EMDR (Devilly, 2002;
Davidson & Parker, 2001). The VA (2010) suggests that aside from the eye movements, other
components of EMDR are the same as cognitive and exposure-based therapies. Spates and
colleagues (2009) reported that without further evidence, the eye movements during sessions are
unnecessary. However, despite the unproductive eye movements, evidence suggests EMDR is as
effective as trauma-focused CBT (DoD, 2010).
Selective serotonin reuptake inhibitors. When PTSD was first added to the DSM in
1980, research in pharmacological treatment was nonexistent, and prescribers had to rely on
symptom overlap with other disorders when making medication decisions. The result was
frequent prescriptions of antidepressants, anxiolytics, and sedative hypnotic medications used
“off label” with very little consistent efficacy observed (Raskin, 2009). Since then, selective
serotonin reuptake inhibitors (SSRIs) have been used as a first-line pharmacological treatment
for PTSD, and a meta-analysis supports their use (Stein, Isper, & Seedat, 2006), with treatment
guidelines suggesting that SSRIs be taken for 12-24 months (Bandelow et al., 2014). However,
Stein and colleagues (2006) reported that studies typically exclude combat Veterans from their
analysis, focusing instead on civilian trauma. In fact, they suggested that research should be
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conducted on the possibility that combat exposure is a predictive factor for SSRI nonresponsiveness in treating PTSD.
This use of SSRIs in treating PTSD is considered a “significant benefit” and “strongly
recommended” (VA, 2010) is largely based on randomized control trials with civilian
populations and rarely target Veteran specific populations. Unfortunately, when randomized
control trials evaluate pharmacological treatments specifically for Veterans, the results are
contradictory to what is observed in comparable civilian populations regarding symptoms
presentation (Friedman, 2006). In fact, the literature has provided evidence since the early 1990s
that combat Veterans may not respond to SSRIs in a similar fashion as survivors of civilian
trauma (van der Kolk et al., 1994). In fact, a VA study conducted between fluoxetine (an SSRI)
and placebo showed that twice as many participants in the placebo group had a significant
decrease in PTSD symptoms (Hertzberg et al., 2000).
Barriers to Treatment
Individual barriers. When evaluating barriers to treatment, factors unique to the
individual may inhibit treatment-seeking behaviors. For example, a frequently endorsed barrier
to care among combat Veterans is practicality in attending weekly appointments (Stecker et al.,
2007). The relative high frequency of appointments when compared to other health-care
professional appointment SPREADS is not a problem unique to Veterans. In a sample of civilian
women with PTSD who chose medication over psychotherapy, ability to attend therapy regularly
was the most frequently reported concern as well (Cochran et al., 2008). Frequently the barriers
to treatment are perceptual rather than realistic, with a positive correlation observed between
PTSD symptoms and perceived barriers to care (Ouimette et al., 2011). That is, those with more
severe symptoms are more likely to report that they cannot attend therapy regularly.
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Geographical distance from treatment opportunities may be a casual factor in treatment
underutilization in rural populations (McCarthy & Blow, 2004). Approximately one third of
OIF/OEF Veterans return to the rural south, where mental-health services are less readily
available (Kirchner et al., 2011). Indeed, the VHA has worked diligently to create rural satellite
clinics and tele-health equipment for use by Veterans. Veterans living in rural areas with a mental
health diagnosis are less likely to report receiving treatment, even more so when specialty care is
required (Wang et al., 2005). Studies have been conducted showing that distance to a VA hospital
is significantly related to fewer psychotherapy services (Cully et al., 2008) regardless of
symptom presentation or demographics (Culley et al., 2010).
A treatment barrier specific to younger combat Veterans is the perception of fit between
themselves and the treatment setting (Ouimetter et al., 2011). When senior citizens are dual
enrolled in Medicare and VA benefits, 94% of seniors use the VA system for their mental health
and inpatient care (Petersen et al., 2010). This has led the average age of patients at the VA to be
approximately 70 years old (Ouimetter et al., 2011). This leaves younger Veterans feeling
uncomfortable as they feel the VHA’s purpose is to serve primarily older Veterans.
Institutional barriers. The institution providing care may be a significant source of
imposed barriers. For example, one commonly cited explanation for low treatment-seeking
behavior is long wait times (Tanielian & Jaycox, 2008; Hoge et al., 2004). Strategies used to
disseminate information are possible barriers to treatment if execution is poor or misguided. In
an effort to make sure that combat Veterans know about available treatment services, the DoD
may also have unintentionally served as an institutional barrier. The timing of education about
services typically occurs shortly after a deployment, and as one Veteran reported, this may not be
the best time.
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When we came back from our deployment, we had to go through all these little classes,
and some of these were mental health classes. Without a doubt, we knew that everybody
was there to help us. The last thing on our mind was wanting that help. We wanted to go
home (Stecker et al., 2007; pp. 1359).
Although education about treatment services may appear to be best presented immediately after
returning from deployment, Stecker and colleagues (2007) suggest that Veterans are not mentally
prepared to retain such information and are more concerned with returning home. By having
soldiers sit through these presentations immediately after returning home, the DoD may
inadvertently be linking treatment with negative feelings.
The clinicians themselves, through misunderstandings about treatment, can become
barrier to effective treatment. One reason might be that clinicians exclude clients from treatments
because the clinician has seen similar individuals excluded from randomized control trials of a
treatment (Ronconi et al., 2014). For example, exposure-based treatments are largely excluded
from clinical consideration due to concerns of inducing anxiety with other comorbid conditions
(Zoellner et al., 2009). Until recently, there was no comprehensive review of inclusion and
exclusion criteria used in randomized clinical trials that corresponded to clinical practice.
However, evidence suggests that exclusion criteria used in clinical trials for participant selection
should not be given strong consideration in clinical practice (Ronconi et al., 2014).
Few VA psychotherapists appear to choose EBTs as an initial approach in treatment of
PTSD (Rosen et al., 2004 Shiner et al., 2013), despite the massive dissemination efforts
educating clincians and promoting benefits of EBTs (Zayfert et al., 2005; Shiner et al., 2013).
Some have suggested patient preference for alternative treatment as a barrier to the delivery of
EBTs for PTSD (Zoellner et al., 2009). Others have suggested a lack of clinical training in EBTs.
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Training and opportunity do not appear to factors as many clinicians tend not to choose EBT for
their patients despite receiving adequate training (Becker, Zayfert & Anderson, 2004). This
suggests other unknown factors are playing a role in treatment choice by clinicians. Clinician
choice of treatment options is an understudied area of research (Ronconi et al., 2014). One
explanation may simply be clinician misunderstanding of PTSD. Although treatments that
promote discussion and narratives of the trauma may be effective to some (Monsoon et al.,
2006), these treatments may be ineffective for others. Rauch et al. (1996) used positron emission
tomography (PET) scans to show decreased activity in Broca’s area (the part of the brain
responsible for speech) during the reading of trauma narratives, suggesting that talking through
trauma may not be possible for some Veterans.
Instead of acknowledging limitations to clinician-preferred treatments, some treatment
theorists give suggestions as to how to work through “resistance.” Foa, Keane, and Friedman
(2000) gave several suggestions, including hypnosis and medication, to work with “resistant”
patients. Rather than attempt to identify ideal populations or conditions that respond better to
specific treatments, they assumed the position that the patient was intentionally resistant to
treatment. Relying on a lack of contrary evidence, they supported their position by stating that
there was no evidence that treatments they outlined (i.e., cognitive therapy, prolonged exposure)
were less effective in specific populations.
Societal barriers. Frequently one of the barriers many Veterans face in seeking treatment
is the concern that others will view them differently if they know the Veteran is in treatment.
Despite the fact that in one study OIF/OEF Veterans did not strongly endorse negative
stereotypes associated with mental illness (Vogt, Fox, & DiLeone, 2014), in a recent analysis,
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post-9/11 combat Veterans reported that workplace stigma was a major concern. Further, their
concerns about career advancement served as a significant barrier.
Treatment-seeking behavior among combat Veterans may be impacted from stigmarelated beliefs. One study found that more than over 75% of post-9/11 combat Veterans
diagnosed with PTSD, depression, of generalized anxiety disorder recognized their diagnosis and
consequences. However, only 40% reported interest in receiving treatment (Brown et al., 2011).
Perceptions of mental-health treatment among military leadership may play a significant role in
treatment seeking. Evidence has shown that enlisted members of the military are likely to have
the same views of mental health stigma as their superior, regardless if that view is positive or
negative (Clark-Hitt, Smith, & Brokerick, 2011). Moreover, when enlisted service members were
asked about their willingness to refer themselves and a subordinate to mental-health treatment,
66% were willing to refer both themselves and others, and only 7% were not willing to refer
themselves or others. No respondents were willing to refer themselves and not their subordinates
(Johnston, Webb-Murphy, Raducha, & Abou, 2011).
Distance is frequently proposed as being a barrier for rural individuals. However, a
stringent evaluation of this claim suggests that societal influence is more of a barrier than
distance (Kirchner et al., 2011). The valuation of self-reliance and independence is prevalent in
rural culture. This combination of values, though adaptive in many situations, is believed to
impede treatment-seeking behavior (Hauenstein et al., 2007).
Cultural differences may significantly lead to comfort in clinical settings as well. As one
combat Veteran stated:
In going into a clinical environment, where you are going to talk about things that hurt
your heart and that cause you great grief and distress, not only do you not know the

33
counselor that you are going to talk to, but you are walking into a sterile environment that
is foreign to you (Stecker et al., 2007 pp. 1352).
PTSD Treatments Revisited: Beyond the VA
In response to barriers of treatment-seeking behavior, there has been a call for novel
treatment options that may be better suited and more appealing to combat Veterans (Vogt et al.,
2014). The following section will cover select novel treatments currently for efficacy among
Veteran populations.
Wilderness experience programs. Wilderness Experience Programs (WEPs) are defined
as “organizations that conduct outdoor programs in the wilderness or comparable lands for
purposes of personal growth, therapy, rehabilitation, education, or leadership/organization
development” (Friese, Hendee, & Kinziger, 1998, p. 40). The idea of using wilderness
environments as a means to improve psychological health is not new (Schuster, 2003). Recently,
researchers and clinicians increased their interest in WEPs to treat combat Veterans to provide a
more comfortable treatment environment (Cassick & Smith, 2014). WEPs do not offer formal
treatment protocols. Instead they operate through an experiential-learning paradigm and give
individuals time to process and reflect on relevant events (Gelkopf, Hasson-Ohayon, Bikman, &
Kravetz, 2013).
Research into WEPs typically includes qualitative interviews or evaluating journals
participants maintain during their experience. One example is a nine-day climb of Mt.
Kilimanjaro, after which Veterans endorsed an increase in self-determination, active coping
skills, and social support (Burke & Utley, 2013). As another example, during a four-day kayak
trip, Veterans reported a decrease in arousal and an increase in positive mood (Dustin, Briker,
Arave, Wall, & Wendt, 2011). As a slightly less compelling example, Veterans who took part in a
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five-day adventure course did not show a decrease in symptoms, but they did evaluate the
program positively and reported learning strategies to better cope with negative emotions (Hyer
et al., 1996). Most studies include reports from short-term programs, usually less than two
weeks, though more intensive programs exist. Veterans who engaged in a six-month hike through
the Appalachian Trail reported an increase in social reconnection, life-improving change, and
psychological healing. They indicated that the main contributing factor to their improvement was
the time away from societal stressors that allowed for this process (Dietrich, Joye, & Garcia,
2015).
Wilderness therapy. WEPs are often designed so that participants experience natural
consequences through guided learning (Gelkopf et al., 2013). Adding to this model, Wilderness
Therapy (WT) combines the use of natural lands with a structured and more traditional treatment
approach (Russell, 2001). A search did not yield studies investigating WT programs for combat
Veterans, but such programs do exist. CBT-based WTs are emerging into the treatment literature,
with evidence supporting increased benefit over traditional CBT treatment for adult populations
with depression (Kim, Lim, Chung, & Woo, 2009), overweight adolescents (Jelalian et al., 2006),
and elderly clients with hypertension (Sung et al., 2012).
D-Cycloserine with exposure therapy. Studies have suggested that N-methyl-Daspartate (NMDA) glutamatergic receptor activity in the amygdala precedes fear learning and
extinction (Norberg, Krystal, & Tolin, 2008). The partial NMDA agonist, D-Cycloserine (DCS)
has been shown in animal models to enhance fear extinction due to increased NMDA receptor
activity (Walker, Ressler, Lu, & Davis, 2002). DCS was originally developed as an antibiotic to
treat tuberculosis (Hardman & Limbird, 2001). However, since the discovery that fear-extinction
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was accelerated with DCS in animal models, interest in the potential use as a PTSD treatment
has emerged.
Working from the theory that DCS coupled with PE would increase treatment gains, de
Kleine and colleagues (2012) found that 64% of their civilian sample showed significant clinical
improvement as compared to the 38% of those in the PE plus placebo condition. However,
within a small Veteran sample (12 per condition) that also received PE and DCS, no benefit was
observed (Litz et al., 2012). The civilian population that showed benefit from administration also
was administered DCS 60 minutes prior to treatment, whereas the military sample was
administered DCS 30 minutes prior to session (both were administered 50 mg). DCS, originally
developed as quick acting treatment, has a half-life of 10 hours, with peak serum levels after 4
hours (Hardman & Hardman, 2001). Interestingly, one study was conducted on Persian combat
Veterans who were administered DCS without any form of adjunctive treatment. The rational
was that soldiers would learn from real-world and informal exposures, and additional treatment
may not be necessary. Although small, a significant difference in self-report endorsement of
avoidance behaviors was observed when compared to the placebo condition (Attari, Rajabi, &
Maracy, 2014). DCS has shown promise in aiding fear extinction in disorders for which a
sympathetic nervous response is a hallmark feature, such as specific phobia. However, more
research is required for PTSD (Hoffmann, Wu, Boettcher, 2013; Norberg, Krystal, & Tolin,
2008).
SSRI with psychotherapy. Guidelines for the treatment of PTSD often refer to SSRIs as
a first-line treatment (VA, 2010). However, others suggest the use of SSRIs as a second-line
treatment in tandem with ongoing psychotherapy (Marshall & Cloitre, 2000). Although reporting
assessments of a small sample (n = 10), one study found that the combination of SSRIs and CBT
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led to significant improvements among Cambodian refugees (Otto et al., 2003). Another study
suggested similar results in a larger sample of American civilians diagnosed with PTSD
(Rothbaum et al., 2006). Unfortunately, these findings failed to replicate in other studies, with
SSRIs showing no advantage over placebo when used in conjunction with PE (Simon et al.,
2008). Arguing that previous studies only included participants with previous ineffective
treatments and “chronic” PTSD, Schneier and colleagues (2012) found that PE in tandem with
SSRIs was more effective than PE and placebo among survivors of the World Trade Center
attack on 9/11. No studies were found that evaluated SSRI in conjunction with psychotherapy for
military populations.
Previous PTSD Treatment-Choice Studies
One solution to increasing attendance and efficacy in treatment for PTSD in combat
Veterans is to simply ask individuals what treatment they prefer. To this end, treatment-choice
studies, or those examining what treatments individuals choose and why, afford insight into the
decision-making process of treatment consumers (Cochran et al., 2008). Clinicians reported a
more positive patient prognosis when treatment rationales were understood and agreed upon by
the patient (Addis & Carpenter, 1999).
Previous treatment-choice studies in PTSD largely focus on treatment for survivors of
sexual assault (Cochran et al., 2008; Zoellner et al., 2003; Zoelner et al., 2009) and by providing
vignettes summarizing a fictional patient, why they are seeking treatment, and treatment
descriptions. In one study comparing treatment choice between PE and sertraline (an SSRI), a
sample of non-trauma exposed women overwhelmingly chose PE over sertraline. Approximately
75% of respondents reported perceptions of effectiveness as a reason. In addition, approximately
half reported that they were weary of medications to treat PTSD (Cochran et al., 2008). These
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results were partially supported by another study evaluating responses from trauma-exposed
participants and those without a history of trauma (Pruitt et al., 2012). When participants without
a history of trauma listened to patient reviews of sertraline and PE, they reported preference for
PE. However, when trauma-exposed participants responded, they endorsed the use of sertraline
and PE in combination. This finding was supported when a similar study gave the vignette in
addition to a measure of PTSD symptoms and treatment choices of PE and Sertraline. All
respondents endorsed the use of PE, but those with a history of trauma endorsed the use of
sertraline higher than those without a trauma history (Zoellner et al., 2009). Taken together, these
studies lend evidence that experience with trauma may alter treatment perception choice.
Previous studies have looked at “treatment interests” among combat Veterans of Iraq and
Afghanistan. However, rather than ask about treatment directly, they listed 17 practical domains
in life (e.g., information on Veterans’ benefits, medication, group therapy) and asked their
interest in improving them (Sayer et al., 2010). In this study, combat Veterans showed most
interest in VA benefits and about schooling, employment or job training. The authors suggested
Veterans were more interested in other practical domains of living and endorsed significantly less
interest in mental-health treatment options.
Current Study
The current study will apply an exploratory inductive reasoning approach to provide
basic data that can later support applied research into treatment attendance and adherence among
military populations. Two samples will represent two distinct populations of military service:
Vietnam-era combat Veterans and post-9/11 combat Veterans. The first aim of this study is to
evaluate for endorsement of treatment options after reading a hypothetical vignette of a soldier
experiencing symptoms consistent of PTSD and look for differences among the two group
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groups of Veterans. The second aim of this study is to evaluate individual factors and how these
may relate to treatment choice. Previous literature provides evidence that personality, rurality,
trauma exposure, and generational cohort influence treatment attendance and adherence. These
factors will be analyzed with the aim of uncovering potential traits that might predict treatment
choice.
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CHAPTER 3: METHOD
Participants
We recruited 218 participants through the online data collection application Mechanical
Turk (mTurk). Only participants with deployments during either the Vietnam Era (02/28/1961 –
05/07/1975; DVA, 2017) or Post 9/11 Era (after 09/11/2001; GPO, 2003) were retained for
analysis, reducing the sample size to 185 (Vietnam Era = 25; Post 9/11 = 160) with 28 women
who were all Post-9/11 Veterans. Participants received one dollar of credit through mTurk
reimbursement accounts as compensation. Demographic information by group, including age,
time in service, number of months deployed, highest obtained military rank, childhood and
current rurality can be found in Table 1. Also in Table 1 are t-test statistics for group
comparisons; these two groups differed significantly with Post 9/11 Veterans reporting a
significantly younger age than Vietnam Veterans, more months deployed, more total time in
service, and higher obtained rank.
Materials and Procedure
Vignette, Treatment Descriptions, and Credibility/Expectancy Questionnaire (CEQ;
Appendix A). Participants were initially presented with a fictional vignette briefly describing the
experience of an individual who returned from combat deployment and is now experiencing
symptoms of PTSD. The vignette was purposely vague in descriptions to avoid potential
confounds that could arise from some participants with combat experience relating to the story
more than others (Foa et al., 2006). The vignette described common themes commonly found in
Veteran narratives rather than specific details.
At the end of the vignette, treatment options were presented in random order with
information about the name of the treatment, description, goals, and potential discomfort.

40
Following each treatment option, the CEQ was presented. The CEQ consisted of six items
divided into two sets. In Set 1, participants rated each treatment using four Likert-type items on a
scale from one (not at all logical) to nine (very logical) in their view of credibility of each
treatment. In Set 2, participants rated the perceived expected efficacy of the treatment using an
item to measure the participant’s expected decrease in symptoms as described in the vignette.
Means scores for each set were obtained. The CEQ has demonstrated good reliability across
multiple populations, including Veteran and college samples (α = .84-.85; Devilly & Borkovec,
2000). Following the last treatment option and CEQ, participants completed the DUKE, PCL-5,
BFI, SSOSH, and then a demographics form.
The Duke Health Profile (DUKE; Appendix B). The DUKE is a 17-item self-report
measure that consists of six health facets (physical, mental, social, general, perceived health, and
self-esteem) and four facets of dysfunction (anxiety, depression, pain, and disability). The DUKE
has been shown to be a reliable brief screener of overall health across multiple domains (α
= .55-.78; Parkerson, Broadhead, & Tse, 1990).
The PTSD Checklist for DSM-5 (PCL-5; Appendix C). The PCL-5 is a 20-item selfreport measure adapted from the original PCL to adhere to diagnostic changes made to the
diagnosis of PTSD in the DSM-5. Participants were asked to rate items on a five-point Likerttype scale that indicates severity of PTSD symptoms during the past month. The original PCL
has consistently demonstrated excellent reliability and validity in multiple populations
(McDonald & Calhoun, 2010) and specifically within military and Veteran populations (Wilkins,
Lang, & Norman, 2011). Limited data are available on the psychometrics of the PCL-5 due to its
recent development. However, an initial study has suggested strong Cronbach’s α of .94 (Liu et
al., 2014).
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The Big Five Inventory-10 (BFI-10; Appendix D). The BFI-10 is a 10-item instrument
that is a shorter version of the original 44-item BFI. This measure assesses personality through
the lexical Big Five factors of personality (Openness, Conscientiousness, Extraversion,
Agreeableness, and Neuroticism; John, Naumann, & Soto, 2008). Participants were asked to rate
on a five-point Likert scale how strongly they agree or disagree with statements about their
personality. Reliability of the BFI has been shown to be strong in North American samples (α
= .75 - .90; John et al., 2008), and the mean correlation of .83 between BFI-10 and BFI suggest
minimal loss of reliability in using the truncated version (Rammstedt & John, 2007). However,
Rammstedt and John (2007) do suggest an additional item to increase the correlation with the
original BFI when assessing Agreeableness. This additional item was used due to the anticipated
impact Agreeableness will have on this study, bringing the total number of items to 11.
Self-Stigma of Seeking Help Scale (SSOSH; Appendix E). The SSOSH is a 10-item
instrument that assesses self-stigma associated with seeking mental health services (Vogel et al.,
2006). Participants were asked to rate on a five-point Likert scale how strongly they agree or
disagree with statements about seeking mental health services. Reliability of the SSOSH has
been shown to be strong in civilian (α = .90; Vogel et al., 2006) and military (α = .90; Skopp et
al., 2012) populations.
Demographics (Appendix F). The information on the demographic form asked
participants to report their age, gender, ethnicity, marital status, education, maternal education,
branch of military service, years of military service, highest obtained military rank, number of
combat deployments, time in months total of combat deployments, and rurality. Rurality was
assessed by asking participants to rate the rurality of both their current and childhood residences
on a scale of 1 (extremely rural) to 7 (extremely urban).
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CHAPTER 4: RESULTS
Preliminary Analyses
Descriptive statistics by group (Vietnam, Post 9/11 Veterans) and t-test comparison
statistics for all measures (i.e., DUKE, PCL-5, BFI, and SSOSH) can be found in Table 2. Post
9/11 Veterans reported lower self-esteem, higher global PTSD symptoms, and more significant
distress from symptoms of intrusion and arousal than Vietnam Veterans. Of note, on the PCL-5,
the averages for both cohorts were above the recommended cut-point for clinical elevation
(clinical significant cut-point = 33; Weathers et al., 2013). No significant differences were found
in personality variables (BFI), self-imposed stigma towards seeking mental health services
(SSOSH), or DUKE domains other than Self-Esteem.
Differences in Treatment Endorsement by Group
The first aim of this study was to evaluate whether Vietnam and Post 9/11 Veterans
differentially endorsed the nine treatment options. To determine if group (Vietnam, Post 9/11)
was related to treatment endorsement, we analyzed these data using two 2 (group) x 9
(treatment)mixed model ANOVAs, one for CEQ credibility as the outcome variable and one for
CEQ expectancy as the outcome variable. The main effect of group on treatment endorsement
was not significant for either credibility or expectancy. For credibility, Mauchly’s test of
sphericity showed a significant violation, χ2(35) = 686.44, p < .001. Based on GreenhouseGeisser adjustments, F(4.05, 740.18) = 1.01, p = .426. For expectancy, Mauchly’s test of
sphericity showed a significant violation, χ2(35) = 486.57, p < .001. Based on GreenhouseGeisser adjustments, F(5.04, 650.26) = .78, p = .379. Means and standard deviations by group
can be found in Table 3.
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Factors Related to Treatment Choice
The second aim of this study was to evaluate individual factors and how they may relate
to treatment choice. Because we did not find differences in treatment choice based on sample, we
collapsed across both groups for subsequent analyses (N = 185). The eight treatments and the notreatment option were evaluated based on credibility and expectancy with several personality,
demographic, and mental health variables entered as potential predictor variables. Since no wellestablished theories on patient-treatment selection are available for comparison, we did not use
forced entry of multiple linear regression (Studenmund & Cassidy, 1987). In addition, suppressor
effects and increase for Type II error are undesirable since this exploratory study could provide
data for hypothesis testing in future studies. Therefore, we used the backward entry method to
retain the highest number of potential predictor variables. These variables can be removed
through forced-entry hypothesis testing in later studies (Field, 2013). Consequently, multiple
regression analyses were conducted for credibility and Expectancy (See Tables 4-12)
CPT (Table 4) credibility was predicted by lower self-stigma, lower symptoms of
depression, and less reactivity and arousal symptoms of PTSD, and a lower endorsement of
extroversion. Higher endorsement of physical pain and avoidance symptoms were predictive of
credibility of CPT. Expectancy of individual symptom decrease was predicted by higher
intrusion and avoidance symptoms of PTSD and less stigma, anxiety, and arousal symptoms of
PTSD. The other treatment with strong VA support, PE (Table 5), had predictive credibility only
by two variables. PE credibility was predicted by lower scores on physical pain and stigma.
Expectancy in symptom reduction was stronger in those higher in intrusion symptoms of PTSD
and less symptoms of anxiety. Credibility of PE in conjunction with D-Cycloserine (Table 6),
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theorized to increase speed of habituation, was predictive by a high endorsement of avoidance
symptoms, less symptoms of arousal, and less self-induced stigma. These factors were also
shown in expectancy of symptom reduction, with the addition of more combat deployments and
higher depression.
EMDR (Table 7) was the only treatment where higher endorsement of self-induced
stigma was related to higher rates of credibility and expectancy. Expectancy of symptom
reduction was only additionally predicted by less negative alterations in cognition and mood.
Credibility was also predicted by fewer number of combat deployments in addition to lower
endorsement of negative alterations in cognitions and mood after trauma and higher endorsement
of self-induced stigma.
SSRI medication alone (Table 8) was only predicted by physical difficulties, specifically
higher endorsement of pain and disability. Expectancy was also predictive by higher pan
endorsement, in addition those with higher endorsement of avoidance symptoms of PTSD and
more likely to be supported by those who are younger in age. When SSRI medication is used in
combination with psychotherapy (Table 9), less self-induced stigma, less anxiety, higher
depression and higher avoidance symptoms become predictive factors. Symptom expectancy was
predicted by less stigma, less intrusion symptoms, and higher avoidance, anxiety, and physical
pain.
The use of WEP as treatment (Table 10) yielded credibility predicted by higher
education, currently more rural, fewer deployments, and less endorsement of arousal.
Expectancy of symptoms reduction was again predicted by higher education, and fewer number
of deployments. Symptoms reduction expectancy was predicted by lower endorsement, fewer
number of deployments, lower endorsement of overall psychological well-being and less
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negative alterations of cognition after trauma. Individuals who were likely to endorse WEP
favorably were also more likely to endorse personality traits consistent with agreeableness.
For WT (Table 11), endorsement of credibility was predicted by fewer symptoms of
arousal, less depression, less physical pain, and fewer number of deployments. However, lower
endorsement of overall psychological well-being was also predictive of higher WT endorsement.
These individuals were also more likely to currently live in more rural environments. Expectancy
in symptoms reduction was again predicted by lower endorsement of overall psychological wellbeing and fewer symptoms of psychological arousal. A current rural environment was predictive
of expectancy, as with credibility, although a childhood urban environment was observed
predictive of expecting higher symptom reduction.
The option to not seek treatment (Table 12) was endorsed as more credible by those with
less arousal symptoms, less physical pain, less depression, and fewer deployments. Conversely,
these individuals were lower on overall psychological well-being. They also endorsed more rural
current environment. In expectancy of symptom reduction, a more rural current environment was
endorsed, however a more childhood urban environment. A lower endorsement of negative mood
was predictive of higher expectancy in reduction, as was lower endorsement of general
psychological well-being.
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CHAPTER 5: DISCUSSION
The purpose of the current study was to explore Veteran reports of perceived credibility
of common and novel PTSD treatments and their expectancy of symptom reduction through
these treatments. We aimed to evaluate previous studies suggesting that treatments have different
outcome and attendance rates between Vietnam and Post-9/11 Veterans (Chard et al., 2010).
Additionally, we sought to determine what factors might influence treatment choice, with the
end-goal of improving treatment attendance and completion.
Treatment Endorsement
Data from this study did not reveal differences in either credibility or expectancy between
Vietnam and Post 9/11 Combat Veterans for any treatments. Previous studies have suggested that
cohort is a stronger predictive factor of treatment choice than psychiatric symptoms, with
Vietnam Veterans more likely to seek treatment (Erbes et al., 2009) and to benefit from
treatment (Resnick, 2009) than Post 9/11 Veterans. Support for the assumption that strength of
endorsement regarding treatment choice would also differ significantly and offer predicative
value (Cochran et al, 2008) was not provided by this study.
Perhaps contributing to these inconclusive findings is the lower than expected
endorsement of treatment when qualitatively comparing our sample to prior samples (e.g. Pruitt
et al., 2012). Although we used a different metric than prior studies, other studies (e.g.,
Rothbaum et al., 2006) have reported better optimism that different treatments will work than in
our study. Statistically, the narrowing range of these data may impact predictive significance.
Sampling may also be a contributor to nonsignificant findings, as previous studies have used
Veterans right before or during treatment or university samples made up primarily of female
participants. In contrast, we used an online sample of Veterans who were mostly men and who
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may have had a range of exposure to treatment in terms of the kinds of treatment and when they
were in treatment that serveas confounds.
Research also has shown different results among female samples with those who have no
trauma history endorsing PE higher than SSRI medication alone and combining PE with SSRIs
(Cochran et al., 2008) and those with a trauma history endorsing the combination of PE and
SSRI higher (Pruitt et al., 2008). Trauma history was not evaluated in the current study due to
online assessment and safety concerns, although all had experienced at least one combat
deployment. Additionally, most of the participants in this study were men (exclusively men in
the Vietnam sample).
Treatment Endorsement Predictors
Prior studies have shown that adherence to and preference for treatment options are
associated with patient factors such as symptoms of depression among Vietnam Veterans (Erbes
et al., 2009), PTSD symptoms among women with trauma history (Cochran et al., 2008), and
personality traits such as conscientiousness and agreeableness predicting better treatment
adherence Bruce et al., 2010). Within our sample, these variables and endorsement of treatment
were inconsistent with prior treatment outcome and treatment choice studies, which is discussed
in detail below. For clarity, we included a summary of model prediction findings in Table 13.
Prior treatment choice studies have shown that, among women, trauma history and PTSD
symptoms were predictive factors of treatment choice (Cohchran et al., 2008; Pruitt et al., 2012).
In this study, total PTSD symptom presentation did not yield the same strength of endorsement.
However, when evaluating endorsement of each specific criterion within the diagnosis criteria as
measured by the PCL-5, significant predictive value was yielded from these scores. For instance,
avoidance symptoms are one of the hallmark symptoms of PTSD and yielded both positive and
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negative predictive value across treatments. Those who scored higher on symptoms of avoidance
were shown to have higher endorsements of CPT, SSRI alone and in conjunction with
psychotherapy, and D-Cycloserine with PE. The descriptions of these treatments stated that
discomforts would occur in session and/or medication would assist in coping/extinguishing the
fear response. Qualitatively, this could suggest that Veterans with higher endorsement of
avoidant symptoms perceived benefits to treatment focusing on confronting the trauma but
wanted assistance in coping with the trauma from either their therapist or medication. Similarly,
symptoms of arousal and reactivity (e.g., hypervigilance) were negative predictors of CPT, PE
with D-Cycloserine, WT, and WEP.
One unexpected contributor of these data is the impact of physical ailments on selection
of mental health treatment. Physical factors such as pain and disability were not considered in
review of prior treatment choice studies. Experiencing physical pain was a negative predictor of
treatments where physical discomfort could be indicated in the provided description, such as PE
and WT. Conversely, physical pain was a positive predictor of treatments with low physical
expectations or involving medications (CPT, SSRI alone, SSRI w/ therapy), meaning that those
in more physical pain were more likely to endorse treatments they perceived carried less physical
demands or discomfort.
The role of stigma in treatment is frequently cited in the literature across virtually all
populations. Specifically among military populations, concerns of career advancement and
perceptions of subordinates and superiors are prevalent. As a Veteran sample, our population
was no longer currently serving in the military and were less likely to experience these external
factors due to increased privacy regulations in the civilian sector. Therefore, we chose a measure
that limited stigma to self-induced stigma that asked questions about self-evaluation. Stigma
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endorsement had a negative relationship with treatments focusing on psychotherapy apart from
EMDR, indicating that, for the most part, the less stigma one felt, the more appealing
psychotherapies were. One possible explanation for the EMDR endorsement compared to other
psychotherapies was the description of EMDR participants read. The description used
highlighted the bilateral tracking in conjunction with processing memories. EMDR description
did not explicitly state, like other psychotherapies, these memories would be shared, discussed,
or vocalized. This could have been viewed by participants as a method of seeking treatment and
not having to risk the potential of increased stigmatization by disclosing painful or embarrassing
narratives or emotions.
The proposed value of evaluating treatment choice is the idea that through the process of
evaluation and selection the patient assumes partial responsibility, and adherence increases with
subsequent improvement (Carpenter et al., 1999). Currently, the dissemination efforts of policy
makers, agencies, and organizations are for providers to only provide evidence-based treatments
(EBTs; Resnick et al., 2009). However, some EBTs do not lead to the same results in real-world
applications as they do in controlled studies, and many researchers are investigating possible
explanations. If treatment choice carries the weight of influence as proposed by previous
research (e.g., Milliken et al., 2007), then one of the potential negating factors of effective
treatment is simply that the patient did not like it for any number of reasons.
The view of the patient actively choosing a treatment that addresses presenting problems
was assumed by Carpenter and colleagues (1999) but never validated. The data found in the
current study could lend evidence that patients endorse treatments that enable, rather than treat,
symptoms of psychological distress. For example, CPT does not focus on behavioral exposure to
anxiety-provoking stimuli to the same degree as PE. Instead, CPT focuses more on cognitive
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alterations and working through “stuck points” with patients. The predictive factors of choosing
CPT were high avoidance and intrusion symptoms and lower depression.
Comfort seeking considerations in treatment may be different throughout the lifespan.
Age was only predicative of SSRI medication alone as treatment. Previous studies (e.g., Zoellner
et al., 2003) suggest medication was more likely endorsed by those who considered the time
commitment of weekly sessions too burdensome, and this could also be reflective in our sample.
Considering the effectiveness of SSRI medications alone with Veterans, this convenience could
also be an enabling behavior. Qualitative explanations were not collected from participants,
which could have provided valuable information into the rationale behind treatment choice.
Symptoms predictive of WT and WEP choice were unique from other treatments in that a
lower general overall psychological well-being was indicated. The DUKE Mental Health domain
is calculated using scores relating to self-esteem, overall mood, motivation, and nervousness.
Symptoms more consistent with a definitive diagnosis were not predictive, or as strong, as
overall well-being. The description did not suggest, as with other treatments, that a specific
symptom or a disorder would be targeted. The patient symptoms description and lack of
predictability with other symptoms could be indicative of a need for an experiential process for
self-fulfillment rather than treatment of a specific disorder. Predicative factors of WEP were also
higher education and a shift from urban childhood setting to rural adult setting, which was not
seen in other treatments. This would appear to be more consistent with integration difficulties as
described in the literature (Shays, 2010), and other treatments described in this study would be
inappropriate due to targeted focus.
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Limitations
The data collected for this study was done so through mTurk, the online data collection
service through Amazon Web Services. Verification of factors measured in this study could not
be absolutely confirmed. The data was examined for unlikely combinations in demographic
reporting (e.g., years of service, year of first deployment, current age), and no improbable
combinations were detected. The use of mTurk, as with any on-line distance study, raises
concerns of requesting information that may elicit strong emotional responses. For this reason we
did not ask about prior trauma history or prior exposure to treatment. This information has
yielded mixed results in previous studies but may have shown relationships in this study that
could have provided useful information.
The use of mTurk may have also allowed for selection bias that we are unable to detect.
Our participants are all part of an online Web Service system and are compensated for their time.
The ability to do so, or the necessity to do so, may have limited both the internal and external
validly of our study. That a significant majority of our sample scored over the clinical cut-off for
symptoms of PTSD and avoidance behaviors is a cardinal symptom, which also limits external
validity (generalizability). Additionally, we did not ask about service connection status or VA
benefits status. This information could have provided insight into ability to use this sample as a
comparison from VA studies.
Future Directions
The current study was exploratory in nature aimed at providing information for future
hypothesis testing. This information, if confirmed by later studies following patient progress,
could assist in creating predictive models for real-world applications to improve treatment
adherence. Additionally, this information could benefit future treatment studies by examining the
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factors that lead to a patient’s expectation of treatment and considering their strength of actual
treatment adherence and efficacy. Another potential future direction would be to use predictive
data as means of understanding why certain populations choose each treatment. If those factors
are understood better, then treatments could be modified to adapt to these differences.
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Table 1
Descriptive Statistics and t-test Statistics for Selected Demographic Variables
Group
Vietnam (n = 25)
Demographic

Post 9/11 (n = 160)
t for Group
Contrast
p-value

M

(SD)

Range

M

(SD)

Range

Age

65.48

2.93

61-71

31.31

4.66

21-40

49.34

<.001

Years in Service

3.76

4.29

2-21

7.34

3.94

4-24

4.18

<.001

Total Months Deployed

12.12

5.26

4-32

14.64

7.24

2-37

2.11

.041

Number of Deployments

1.12

0.44

1-3

2.07

1.01

1-6

7.99

<.001

Highest Obtained Rank

5.16

2.72

3-17

5.91

2.51

3-16

1.37

.173

Rurality in Childhood

2.32

1.41

1-7

4.14

1.35

1-6

6.23

<.001

Current Rurality

4.27

1.31

2-7

3.13

1.08

1-5

6.63

<.001

Note. t for group contrast with 183 df.
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Table 2
Descriptive Statistics and t-test Statistics for Mental Health, Personality, and Stigma Measures
Group
Vietnam (n = 25)

Post 9/11 (n = 160)
t for Group
Contrast
p-value

Measure
M
(SD)
Range
M
(SD)
Range
DUKE
Physical Health
69.20
25.97
10-100
73.50
20.07
10-100
0.96
.341
Mental Health
67.20
15.95
50-100
71.75
16.62
30-100
1.28
.202
Social Health
56.00
14.72
30-100
48.44
18.80
10-100
1.91
.057
General Health
64.13
14.22
40-93.33
64.56
13.03
30-100
0.15
.888
Anxiety
40.65
13.67
0-66.64
43.11
19.25
0-83.33
0.79
.437
Depression
38.40
12.14
10-50
38.44
14.86
10-80
0.01
.989
Pain
46.00
35.12
0-100
34.69
29.67
0-100
1.73
.086
Disability
------4.06
15.83
0-100
----Self-Esteem
71.60
17.94
40-90
60.44
18.30
20-100
2.84
.005
PCL-5 Total
42.60
12.67
14-60
49.26
12.69
0-75
2.44
.016
Intrusion Symptoms
3.00
0.75
1.8-4.4
3.4
0.68
1-5
2.64
.009
Avoidance Symptoms
3.26
1.02
1.5-4.5
3.55
0.79
1-5
1.67
.096
Alterations in Mood
3.20
0.73
1.71-4
3.47
0.70
1-4.71
1.83
.070
Alterations in Arousal
3.11
0.59
1.67-4
3.47
0.69
1-4.67
2.46
.015
BFI
Openness
4.80
2.58
2-10
5.45
2.61
2-10
1.16
.247
Contentiousness
6.81
2.40
4-10
6.70
2.28
2-10
0.20
.840
Extraversion
5.96
1.86
2-8
6.03
2.12
2-9
0.15
.874
Agreeableness
5.52
1.94
3-8
5.79
1.99
3-10
0.64
.521
Neuroticism
6.76
2.07
1-10
6.63
2.11
2-10
0.29
.766
SSOSH
28.72
5.61
13-42
28.89
5.95
12-42
0.13
.895
Note. DUKE = Duke Health Profile; PCL-5 = Title PTSD Checklist for DSM-5; BFI = Big Five Inventory; SSOSH = Self-Stigma of
Seeking Help Scale; t for group contrast with 183 df.
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Table 3
Descriptive Statistics for Credibility and Expectancy by Group and Treatment
Credibility
Vietnam (n = 25)
Treatment Option

Expectancy

Post 9/11 (n = 160)

Vietnam (n = 25)

Post 9/11 (n = 160)

M

(SD)

M

(SD)

M

(SD)

M

(SD)

CPT

3.00

1.36

3.31

1.25

35.20

34.90

39.56

26.31

PE

3.70

1.41

3.59

1.04

40.40

25.74

42.00

19.16

EMDR

1.84

1.17

2.00

1.25

18.40

18.64

19.31

17.09

SSRI

2.63

1.22

2.63

1.35

18.40

18.86

27.38

21.26

WEP

3.69

1.52

3.90

1.48

44.80

23.12

42.06

22.43

WT

4.39

1.93

4.50

1.55

48.80

24.72

59.13

21.47

D-Cycloserine

3.43

0.88

3.26

1.41

37.20

23.19

37.88

20.04

SSRI/Therapy Combo

3.29

1.16

3.21

1.41

38.80

16.41

37.88

21.90

No Treatment

1.77

0.97

1.32

0.89

17.60

18.32

15.88

20.45

Note. CPT = Cognitive Processing Therapy; PE = Prolonged Exposure; EMDR = Eye Movement Desensitization and Reprocessing;
SSRI = Selective Serotonin Reuptake Inhibitor; WEP = Wilderness Experience Program; WT = Wilderness Therapy.
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Table 4
Multiple Regression Model Outcomes for Cognitive Processing Therapy
B

SE B

Constant

6.01

0.71

SSOSH

-0.07

0.02

BFI Extroversion

-0.08

DUKE Depression

Beta

t

p

8.42

<.001

-0.31

3.71

<.001

0.04

-0.14

2.01

.047

-0.03

0.08

-0.39

4.16

<.001

DUKE Pain

0.02

0.01

0.38

3.97

<.001

PCL-5 Avoidance

0.51

0.15

0.33

3.47

.001

PCL-5 Alterations in Arousal

-0.36

0.17

-0.19

2.11

.036

Constant

58.015

12.041

4.82

<.001

DUKE Anxiety

-0.261

0.135

-0.176

1.93

.055

SSOSH

-1.337

0.409

-0.286

3.27

.001

PCL-5 Intrusion Symptoms

13.762

4.371

0.357

3.15

.002

PCL-5 Avoidance

5.502

2.996

0.165

1.84

.068

-10.121

4.59

-0.253

2.21

.029

Credibility

2

R = .216
Expectancy

PCL-5 Alterations in Arousal

R2 = .160
Note. SSOSH = Self-Stigma of Seeking Help Scale; BFI = Big Five Inventory; PCL-5 = PTSD
Checklist for DSM-5; DUKE = Duke Health Profile.
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Table 5
Multiple Regression Model Outcomes for Prolonged Exposure Therapy
B

SE B

Constant

4.84

0.01

DUKE Pain

-0.01

0.03

SSOSH

-0.03

0.02

Constant

41.44

6.83

DUKE Anxiety

-0.35

0.09

PCL-5 Intrusion Symptoms

4.57

2.26

Beta

t

p

12.71

<.001

-0.31

4.05

<.001

-0.16

2.05

.042

6.09

<.001

-0.33

4.05

<.001

0.16

2.02

.045

Credibility

2

R = .162
Expectancy

R2 = .083
Note. SSOSH = Self-Stigma of Seeking Help Scale; PCL-5 = PTSD Checklist for DSM-5; DUKE
= Duke Health Profile.
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Table 6
Multiple Regression Model Outcomes for D-Cycloserine and PE Combination
B

SE B

6.59

0.47

-0.70

0.15

SSOSH

-0.13

PCL-5 Avoidance

Beta

t

p

14.029

<.001

-0.36

4.76

<.001

0.01

-0.57

9.05

<.001

0.77

0.12

0.47

6.46

<.001

Constant

77.637

6.825

11.375

<.001

SSOSH

-2.046

0.223

-0.59

9.169

<.001

PCL-5 Avoidance

8.208

1.64

0.332

5.005

<.001

PCL-5 Intrusion Symptoms

-9.937

1.994

-0.348

4.983

<.001

Number of Deployments

3.048

1.126

0.15

2.707

.007

DUKE Depression

0.46

0.086

0.326

5.347

<.001

Credibility
Constant
PCL-5 Alterations in
Arousal

R2 = .429
Expectancy

2

R = .473
Note. SSOSH = Self-Stigma of Seeking Help Scale; PCL-5 = PTSD Checklist for DSM-5; DUKE
= Duke Health Profile.
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Table 7
Multiple Regression Model Outcomes for Eye Movement Desensitization and Reprocessing
B

SE B

Constant

4.09

0.61

SSOSH

0.05

0.02

Number of Deployments

-0.21

PCL-5 Alterations in Mood

Beta

t

p

6.71

<.001

0.21

2.80

.006

0.09

-0.17

2.40

.018

-0.76

0.14

-0.43

5.48

<.001

Constant

15.97

7.14

2.24

.026

SSOSH

0.90

0.23

0.31

3.87

<.001

PCL-5 Alterations in Mood

-6.60

1.96

-0.27

-3.37

.001

Credibility

R2 = .186
Expectancy

R2 = .103
Note. SSOSH = Self-Stigma of Seeking Help Scale; PCL-5 = PTSD Checklist for DSM-5.
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Table 8
Multiple Regression Model Outcomes for SSRI Medication
B

SE B

Constant

2.31

0.15

DUKE Pain

0.01

0.01

DUKE Disability

0.02

0.01

Constant

13.63

8.68

DUKE Pain

0.12

0.05

PCL-5 Avoidance

5.65

1.82

Beta

t

p

15.64

<.001

0.169

2.33

.021

0.163

2.24

.026

1.57

.118

0.18

2.52

.012

0.22

3.11

.002

Credibility

2=

R

.054

Expectancy

R2 = .122
Note. PCL-5 = PTSD Checklist for DSM-5; DUKE = Duke Health Profile.
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Table 9
Multiple Regression Model Outcomes for SSRI Medication and Therapy Combination
B

SE B

Constant

4.94

0.41

SSOSH

-0.14

0.02

PCL-5 Avoidance

0.26

DUKE Anxiety
DUKE Depression

Beta

t

p

12.18

<.001

-0.59

9.74

<.001

0.09

0.16

3.05

.003

-0.04

0.01

-0.52

6.15

<.001

0.08

0.01

0.80

10.75

<.001

Constant

73.60

5.94

12.39

<.001

DUKE Pain

0.14

0.04

0.20

3.56

<.001

SSOSH

-2.95

0.21

-0.83

14.04

<.001

PCL-5 Avoidance

17.50

1.42

0.68

12.32

<.001

DUKE Anxiety

0.42

0.07

0.37

5.88

<.001

PCL-5 Intrusion
Symptoms

-10.51

1.741

-0.35

6.04

<.001

Credibility

R2 = .578
Expectancy

R2 = .646
Note. SSOSH = Self-Stigma of Seeking Help Scale; PCL-5 = PTSD Checklist for DSM-5; DUKE
= Duke Health Profile.

TREATMENT CHOICE

79

Table 10
Multiple Regression Model Outcomes for Wilderness Experience Program
B

SE B

Beta

t

p

6.17

0.70

8.82

<.001

-0.58

0.15

-0.27

3.87

Education

0.26

0.10

0.19

2.66

.009

Number of Deployments

-0.26

0.10

-0.17

2.48

.014

Current Rurality

-0.19

0.08

-0.16

2.34

.020

Constant

74.69

12.64

5.91

<.001

Education

3.33

1.45

0.16

2.27

.025

Months of Deployment

-0.48

0.22

-0.15

2.19

.030

DUKE Mental Health

-0.20

0.09

-0.15

2.12

.035

BFI Agreeableness

1.56

0.77

0.14

2.02

.045

PCL-5 Intrusion Symptoms

-9.24

2.15

-0.30

4.30

<.001

Credibility
Constant
PCL-5 Alterations in
Arousal

<.001

2

R = .141
Expectancy

R2 = .162
Note. SSOSH = Self-Stigma of Seeking Help Scale; BFI = Big Five Inventory; PCL-5 = PTSD
Checklist for DSM-5; DUKE = Duke Health Profile.

TREATMENT CHOICE

80

Table 11
Multiple Regression Model Outcomes for Wilderness Therapy
B

SE B

9.31

0.90

-0.42

0.16

DUKE Pain

-0.01

DUKE Mental Health

Beta

t

p

10.34

<.001

-0.18

2.63

.009

0.01

-0.18

2.09

.038

-0.02

0.01

-0.16

2.34

.020

Current Rurality

-0.21

0.09

-0.16

2.29

.023

Number of Deployments

-0.27

0.11

-0.17

2.54

.012

DUKE Depression

-0.02

0.01

-0.17

1.99

.048

Constant

98.86

13.89

7.12

<.001

Childhood Rurality

2.40

1.07

0.16

2.25

.026

DUKE Mental Health

-0.21

0.10

-0.16

2.13

.035

Current Rurality

-3.71

1.31

-0.21

2.83

.005

PCL-5 Alterations in Mood

-6.77

2.26

-0.21

2.99

.003

Credibility
Constant
PCL-5 Alterations in
Arousal

R2 = .204
Expectancy

R2 = .118
Note. PCL-5 = PTSD Checklist for DSM-5; DUKE = Duke Health Profile.
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Table 12
Multiple Regression Model Outcomes for No Treatment
B

SE B

Constant

3.70

0.28

DUKE Pain

0.01

0.00

PCL-5 Avoidance

-0.33

DUKE Anxiety
PCL-5 Intrusion Symptoms

Beta

t

p

13.24

<.001

0.17

2.46

<.001

0.08

-0.30

4.16

.047

0.01

0.00

0.23

2.92

<.001

-0.55

0.10

-0.43

5.68

<.001

Constant

58.02

12.04

4.82

<.001

SSOSH

-0.26

0.14

-0.18

1.93

.055

PCL-5 Avoidance

-1.34

0.41

-0.29

3.27

.001

DUKE Anxiety

13.76

4.37

0.38

3.15

.002

PCL-5 Intrusion Symptoms

5.50

3.01

0.17

1.84

.068

Credibility

R2 = .23
Expectancy

R2 = .118
Note. SSOSH = Self-Stigma of Seeking Help Scale; PCL-5 = PTSD Checklist for DSM-5; DUKE
= Duke Health Profile.

Running head: TREATMENT CHOICE

82

Table 13
Summary of Significant Model Findings Across all Nine Treatment Options
Meds +
PE
C
E

SSRI +
therapy
C
E

CPT
PE
EMDR
SSRI
WEP
WT
No Tx
Variable
C
E
C
E
C
E
C
E
C
E
C
E
C
E
Education
+
+
Childhood Rurality
+
Current Rurality
Number of Deployments
+
Months of Deployment
DUKE Mental Health
DUKE Anxiety
+
+
+
DUKE Depression
+
+
DUKE Pain
+
+
+
+
+
DUKE Disability
+
PCL-5 Intrusion Symptoms
+
+
+
+
PCL-5 Avoidance
+
+
+
+
+
+
PCL-5 Alterations in Mood
PCL-5 Alterations in Arousal
BFI Extraversion
BFI Agreeableness
+
SSOSH
+
+
Note. C = Credibility; E = Expectancy; CPT = Cognitive Processing Therapy; PE = Prolonged Exposure; Meds + PE = D-Cycloserine
with Prolonged Exposure; EMDR = Eye Movement Desensitization and Reprocessing; SSRI = Selective Serotonin Reuptake Inhibitor;
WEP = Wilderness Experience Program; WT = Wilderness Therapy; No Tx = No treatment; DUKE = Duke Health Profile; PCL-5 =
PTSD Checklist for DSM-5; BFI = Big Five Inventory; SSOSH = Self-Stigma of Seeking Help Scale.
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Appendix A

Vignette, Treatment Descriptions, and Credibility/Expectancy Questionnaire
Vignette
Instructions: Please read the following story. You will be asked for your opinion on the next
several pages.
Peyton enlisted in the United States Military and shortly after was assigned to a sixmonth tour in a combat zone. During the deployment Peyton’s daily routine was unpredictable,
with frequent shifts between active combat and periods of calm. However, Peyton knew the
danger inherent in the environment and was always vigilant to potential threats and ready to act
at a second’s notice. After deployment, Peyton immediately returned to civilian routines. Shortly
after returning home, Peyton began experiencing physical reactions to sights, sounds, and smells
that were similar to those experienced during deployment. Peyton then began to avoid reminders
of the deployment because the physical reactions were too stressful. Peyton’s personal life was
also impacted, as activities that were once enjoyed were no longer interesting. Peyton felt the
need to always be on guard, which led to trouble concentrating, always being on the lookout for
threats, and constant irritability. Peyton began staying home more and increasingly cutting back
on the number of family and friends seen on a regular basis. A few of Peyton’s closest family and
friends noticed this change and suggested Peyton should seek mental-health treatment.
Treatment Descriptions
Instructions: Consider Peyton’s story and the following treatment options. After reading each
treatment option, please answer the questions about each treatment choice.

Name of treatment: Cognitive Processing Therapy (CPT)
Description: CPT typically includes 12 weekly sessions and involves discussion, learning
coping skills, and writing about the event.
Goals: CPT primarily focuses on the thoughts and emotions surrounding the traumatic event
to alleviate the psychological distress impacting current thoughts, emotions, and behaviors.
Potential Discomforts: It is possible that discomfort is experienced during treatment as the
individual is asked to recall thoughts and emotions related to the event.
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Name of treatment: Prolonged Exposure Therapy (PE)
Description: PE typically includes 8-15 weekly sessions and involves imagined and real
exposure to situations, objects, and memories.
Goals: PE primarily focuses on the behaviors that maintain symptoms by evaluating
avoidance behaviors and then confrontation to what is avoided. Confrontation occurs
repeatedly until negative thoughts and bodily sensations from anxiety are no longer
experienced.
Potential Discomforts: Confrontations will initially trigger feelings of anxiety.

Name of treatment: Eye Movement Desensitization and Reprocessing (EMDR)
Description: EMDR typically includes 8-15 weekly sessions and focuses on processing
distressing memories while following the therapist’s fingers with his/her eyes left to right.
Goals: The goal of EMDR is to reduce negative thoughts and emotions associated with the
traumatic event.
Potential Discomforts: It is possible that discomfort is experienced during treatment as the
individual is asked to recall thoughts and emotions related to the event.

Name of treatment: Selective Serotonin Reuptake Inhibitors (SSRIs)
Description: SSRIs are prescription medications that increase the amount of serotonin in the
brain. Typically, treatment involves taking a pill once daily.
Goals: SSRIs are prescribed to alleviate distress through increasing mood-enhancing
chemicals in the brain.
Potential Discomforts: Side effects may include nausea, decreased sexual interest, and feeling
drowsy. Although, these side effects do not occur in everyone.
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Name of treatment: Wilderness Experience Program (WEPs)
Description: WEPs are a form of treatment through using natural setting to “decompress”
from a traumatic event. Typically this occurs through an extended hiking, kayaking, or
mountain climbing trip.
Goals: The goal is for the individual to remove him/herself from stressors found in society and
allows time to process the event at his/her own pace.
Potential Discomforts: Discomforts may vary depending on the type of experience in the
wilderness that is chosen.

Name of treatment: Wilderness Therapy Programs (WT)
Description: WEPs are a form of treatment through using natural setting to “decompress”
from a traumatic event. Typically this occurs through an extended hiking, kayaking, or
mountain climbing trip and includes periodic in-person or electronic therapy (e.g. video chat,
email) to assist in processing.
Goals: The goal is for the individual to remove him/herself from stressors found in society and
allows time to process the event at his/her own pace.
Potential Discomforts: Discomforts may vary depending on the type of experience in the
wilderness that is chosen.

Name of treatment: Medication-Assisted Therapy
Description: Individuals take an antibiotic medication 30 minutes before each therapy session.
The antibiotic medication has been shown to assist in fear extinction when used during
treatment sessions.
Goals: The goal is to increase the effectiveness of each treatment session.
Potential Discomforts: The medication does not alleviate potential discomfort during the
course of the psychological treatment caused by recalling stressful events.
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Name of treatment: antidepressant medication with traditional talk therapy
Description: Individuals take a daily antidepressant medication while attending traditional
weekly sessions of traditional talk therapy.
Goals: The goal is to decrease symptoms that are experienced so that focus can be placed on
psychological treatment.
Potential Discomforts: Discomforts from therapy may be significantly alleviated, but you may
experience the side-effects of the medication which can include nausea, decreased sexual
interest, and feeling drowsy.

No treatment
Description: Some individuals do not seek treatment find strategies to manage and overcome
symptoms themselves. Some individuals are successful while others are not and symptoms are
maintaining for a lifetime. There is no “typical” time of recovery.
Potential Discomforts: Discomforts vary across individuals.

Credibility/Expectancy Questionnaire
These questions will be asked at the end of each treatment description.
1. How logical does the treatment described to you seem?
1------------2------------3-----------4------------5------------6------------7
Not at all
Extremely
2. How successfully do you think this treatment will be in reducing symptoms?
1------------2------------3-----------4------------5------------6------------7
Not at all
Extremely
3. How confident would you be in recommending this treatment to a friend?
1------------2------------3-----------4------------5------------6------------7
Not at all
Extremely
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4. How much improvement in symptoms do you think will occur?
1------------2------------3-----------4------------5------------6------------7
Not at all
Extremely
5. How much do you really feel that this treatment will help reduce symptoms?
1------------2------------3-----------4------------5------------6------------7
Not at all
Extremely
6. How much improvement in symptoms do you really feel will occur from this treatment?
1------------2------------3-----------4------------5------------6------------7
Not at all
Extremely
7. Please rate the following:
0%

By the end of the treatment
period, how much
improvement in symptoms do
you think will occur?

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%
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Appendix B
Duke Health Profile

Instructions: Here are some questions about your health and feelings. Please read each question
carefully and check your best answer. You should answer the questions in your own way. There
are no right or wrong answers.
Yes,
describes me
exactly

Somewhat
describes me

No, doesn’t
describe me
at all

Some

A Lot

None

Some

A Lot

None

Some

A Lot

None

1-4 Days

5-7 Days

1. I like who I am……………………………………..
2. I am not an easy person to get along
with……………………………………………………
3. I am basically a health
person……………………............................................
4. I give up too easily…………………………………
5. I have difficult
concentrating…………………………………………
6. I am happy with my family
relationships…………………………………………..
7. I am comfortable being around
people………………………………………………….

TODAY would you have any physical trouble or difficulty:
None
8. Walking up a flight of stairs………………………
9. Running the length of a football field…………….

During the PAST WEEK: How much trouble have you had with:
10. Sleeping……………………………………………
11. Hurting or aching in any part of your body……..
12. Getting tired easily………………………………..
13. Feeling depressed or sad………………………….
14. Nervousness……………………………………….

During the PAST WEEK: How often did you:
15. Socialize with other people (talk or visit with
friends or relatives)……………………………………
16. Take part in social, religious, or recreation
activities (meetings, church, movies, sports, parties).

During the PAST WEEK: How often did you:
17. Stay in your home, nursing home, or hospital
because of sickness, injury, or other health problem.

TREATMENT CHOICE

89
Appendix C
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Appendix D
Big Five Inventory-10

Instructions: Please circle the number for each item that best describes how well you feel
following statements describe your personality.
I see myself as someone
who…

Disagree
strongly

Disagree
a little

Neither
agree nor
disagree

Agree a
little

Agree
strongly

… is reserved

1

2

3

4

5

… is generally trusting

1

2

3

4

… tends to be lazy

1

2

3

4

5

… is relaxed, handles stress
well

1

2

3

4

5

… has few artistic interests

1

2

3

4

5

… is outgoing, sociable

1

2

3

4

5

… tends to find fault with
others

1

2

3

4

5

… does a thorough job

1

2

3

4

5

… gets nervous easily

1

2

3

4

5

… has an active imagination

1

2

3

4

5

… is considerate and kind to
almost everyone

1

2

3

4

5

5
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Appendix E
Self-Stigma of Seeking Help Scale

Instructions: People at times find that they face problems for which they would consider seeking
professional help. This can bring up reactions about what seeking help would mean. Please use
the 5-point scale to rate the degree to which each item describes how you might react if you
decided you needed to seek out professional help.

1. I would feel inadequate if I went to a
therapist for psychological help.
2. My self-confidence would NOT be
threatened if I sought professional help.
3. Seeking psychological help would make me
feel less intelligent.
4. My self-esteem would increase if I talked to
a therapist.
5. My view of myself would not change just
because I made the choice to see a therapist.
6. It would make me feel inferior to ask a
therapist for help.
7. I would feel okay about myself if I made the
choice to seek professional help.
8. If I went to a therapist, I would be less
satisfied with myself.
9. My self-confidence would remain the same
if I sought professional help for a problem I
could not solve.
10. I would feel worse about myself if I could
not solve my own problems.

Strongly
Disagree

Disagree

Neutral

Agree

Strongly
Agree

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5
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Appendix F
Demographics

1. What is your age?
2. What is your gender?
Male

Female

3. What is your ethnicity?
4. What is your marital status?
Single

Married

Separated

Divorced

Widow (er)

5. What is your highest level of obtained education?
Some High School

High School Diploma or Equivalent

Associates Degree

Bachelors Degree

Masters Degree

Some College
Doctorate

6. What is the highest level of obtained education for your mother?
Unsure

Some High School

Some College

Diploma or equivalent

Associates Degree

Bachelors

Masters

7a. Are you currently in ROTC?
Yes

No

7b. If so, how long have you been in the ROTC?
7c. After you graduate college, do you plan on joining the military?
7d. If so, which branch of service will you join?
8a. Are you currently or have you ever been in the US military?

Doctorate
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8b. If so, please indicate your branch of military service:
Marine Corps

Air Force

ARMY

Navy

Coast Guard

8c. Please indicate how long you were in the military:
8d. What was your highest obtained military rank?
8e. Are you currently active duty, national guard, reserve, or Veteran?
9a. Have you ever served a combat deployment?
9b. Number of combat deployments:
9c. Approximate time in months of all deployments combined:
10. How would you describe the childhood environment that you feel has influenced you
the most today?
|--------------|-------------|---------------|--------------|-------------|--------------|-------------|
Extremely
Rural

Very
Rural

Somewhat
Rural

Slightly
Rural

Slightly
Urban

Somewhat
Urban

Very
Urban

Extremely
Urban

11. How would you describe the environment were you currently reside?
|--------------|-------------|---------------|--------------|-------------|--------------|-------------|
Extremely
Rural

Very
Rural

Somewhat
Rural

Slightly
Rural

Slightly
Urban

Somewhat
Urban

Very
Urban

Extremely
Urban

